Clinical Trial Update: Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update evaluating zoledronic acid as a single agent or added to chemotherapy for high-grade osteosarcoma in Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Zoledronic acid (Zometa) (zoledronic acid)

Snippet

Sponsor: Tata Memorial Hospital | Conditions: Osteosarcoma | Phase 2, Phase 3 | Status: UNKNOWN